Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $37,392,607 | $37,685,346 | $34,990,699 | $36,807,763 |
| - Cash | $12,958,746 | $13,715,963 | $13,523,933 | $13,507,968 |
| + Debt | $32,210,597 | $32,064,371 | $31,696,783 | $29,767,060 |
| Enterprise Value | $56,644,458 | $56,033,754 | $53,163,549 | $53,066,855 |
| Revenue | $10,094,109 | $9,420,323 | $10,155,307 | $10,449,076 |
| % Growth | 7.2% | -7.2% | -2.8% | – |
| Gross Profit | $4,890,940 | $4,500,027 | $4,679,332 | $5,022,862 |
| % Margin | 48.5% | 47.8% | 46.1% | 48.1% |
| EBITDA | $1,694,193 | $1,677,068 | $1,461,754 | $1,819,091 |
| % Margin | 16.8% | 17.8% | 14.4% | 17.4% |
| Net Income | $937,210 | $764,758 | $759,244 | $785,844 |
| % Margin | 9.3% | 8.1% | 7.5% | 7.5% |
| EPS Diluted | 0.35 | 0.29 | 0.29 | 0.3 |
| % Growth | 20.7% | 0% | -3.3% | – |
| Operating Cash Flow | $1,078,321 | $1,055,680 | $0 | $1,863,169 |
| Capital Expenditures | -$955,311 | -$1,118,595 | -$1,383,241 | -$933,593 |
| Free Cash Flow | $123,009 | -$62,916 | $107,103 | $146,041 |